Organization · Venture Capital
Curie.Bio
Curie.Bio is a seed-stage venture capital firm and therapeutics accelerator based in Boston, MA, focusing on empowering biotech founders. They provide capital and operational support to help early-stage therapeutics companies advance from concept to clinical trials.
Overview
What Curie.Bio does
What Curie.Bio is
Curie.Bio is a seed-stage venture capital firm and therapeutics accelerator based in Boston, MA, focusing on empowering biotech founders. They provide capital and operational support to help early-stage therapeutics companies advance from concept to clinical trials.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Curie.Bio elsewhere
Open the official website or a supported primary organization account.
Capability profile
Curie.Bio as a funder
Investment thesis
Curie.Bio aims to empower biotech founders by providing them with the necessary seed capital and operational support to reach critical milestones, allowing them to focus on scientific innovation rather than infrastructure.
Focus narrative
Curie.Bio invests in companies at various stages, from concept-stage to clinical trials, across any modality and therapeutic area. Their investment strategy includes a Seed Fund that typically invests between $5 million and $15 million to help advance therapies through preclinical milestones, followed by further funding through their Breakout Fund to support clinical trials.
Value beyond capital
Curie.Bio provides operational support, project management, and access to a network of experts and resources to help founders efficiently develop their drug candidates. Their model allows founders to focus on scientific innovation while benefiting from the firm's extensive experience in drug discovery and development.
Terms and economics
- Typical check
- $5,000,000–$15,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 26
Portfolio context
Curie.Bio has contributed to the development of over 100 drugs currently in clinical trials and has been involved in the approval of 44 medicines. Notable drugs developed with their support include TIBSOVO®, IDHIFA®, PYRUKYND®, GRASTEK®, LUMAKRAS®, and KEYTRUDA®. Their portfolio includes companies like Forward Therapeutics, Astoria Biologica, Decrypt Biomedicine, and Differentiated Therapeutics.
Common questions
What to know about Curie.Bio
Upseed classifies Curie.Bio under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.